KAT6 inhibitor MEN2312
Term · Oncology and biomedicine · MLC-T-ONC-014633
An orally bioavailable inhibitor of MYST histone acetyltransferase (HAT) KAT6, with potential antineoplastic activity. Upon oral administration, KAT6 inhibitor MEN2312 targets and binds to KAT6, and inhibits the acetylation of histones and other nonhistone substrates. This may disrupt gene expression and inhibit the proliferation of tumors that overexpress KAT6. KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), commonly amplified genes in solid tumors, play key roles in cell cycle regulation and in tumorigenesis.
| Identifier | MLC-T-ONC-014633 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | KAT6A/B inhibitor MEN2312; KAT6A/KAT6B inhibitor MEN2312 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014633",
"term": "KAT6 inhibitor MEN2312",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of MYST histone acetyltransferase (HAT) KAT6, with potential antineoplastic activity. Upon oral administration, KAT6 inhibitor MEN2312 targets and binds to KAT6, and inhibits the acetylation of histones and other nonhistone substrates. This may disrupt gene expression and inhibit the proliferation of tumors that overexpress KAT6. KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), commonly amplified genes in solid tumors, play key roles in cell cycle regulation and in tumorigenesis.",
"synonyms": [
"KAT6A/B inhibitor MEN2312",
"KAT6A/KAT6B inhibitor MEN2312"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/kat6-inhibitor-men2312/"
}
Record 9,736 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.